Sensorion Reports Full-Year 2022 Financial Results and Business Update
CTA filing for OTOF-GT planned for Q2 2023 Presented new preclinical data supporting continued progress of OTOF-GT, and potential for safe and efficient clinical translation of gene therapy
Source: finanznachrichten.de